Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases

Inflammatory bowel disease (IBD) is treated with a variety of immunomodulating and immunosuppressive therapies; however, for the majority of cases, these therapies are not targeted for specific disease phenotypes. Monogenic IBD with causative genetic defect is the exception and represents a disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Levine, Anne E., Mark, Dominique, Smith, Laila, Zheng, Hengqi B., Suskind, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059893/
https://www.ncbi.nlm.nih.gov/pubmed/36986830
http://dx.doi.org/10.3390/pharmaceutics15030969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059893/
https://www.ncbi.nlm.nih.gov/pubmed/36986830
http://dx.doi.org/10.3390/pharmaceutics15030969

Ejemplares similares